This site is informational, not medical advice

What The GLP Report is

The GLP Report is an editorial publication covering the GLP-1 weight-loss telehealth category. We report pricing, clinical oversight structure, medication offerings, public review scores, and regulatory status for a range of providers so readers can make informed research decisions. We cite primary sources for every factual claim.

What The GLP Report is not

We are not a medical provider. We are not your healthcare provider. Nothing on this site is a diagnosis, a prescription, a treatment recommendation, or a substitute for consultation with a qualified healthcare professional. No content on the site constitutes a doctor-patient relationship, nor should it be construed as personal medical advice.

Before starting any GLP-1 treatment

Consult a qualified healthcare professional. GLP-1 medications (semaglutide, tirzepatide, liraglutide) are powerful prescription drugs with meaningful contraindications and side effects. Common side effects include nausea, vomiting, diarrhea, and constipation. More serious risks include pancreatitis, gallbladder disease, and — for medullary thyroid carcinoma — a boxed warning for people with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). GLP-1 medications are not recommended for pregnancy.

Individual results vary. Clinical trial outcomes reported on this site reflect aggregate trial populations and may not reflect the outcomes of any individual reader. The decision to begin, continue, or stop any medication should be made in partnership with a clinician who knows your medical history.

Compounded vs. FDA-approved medications

We clearly label the FDA status of every medication discussed on the site. FDA-approved brand-name medications (Wegovy, Zepbound, Ozempic used off-label, Mounjaro used off-label) have completed clinical trials and manufacturing oversight. Compounded medications are prepared by 503A or 503B pharmacies under the FDA’s compounding framework; they are not FDA-approved products. The regulatory status of compounded GLP-1 medications has evolved meaningfully since 2024, and continues to evolve. Our coverage reflects our most recent verification date.

In an emergency

If you are experiencing a medical emergency, call 911 or your local emergency number. Do not rely on any telehealth provider — or this site — in an emergency.

Accuracy & freshness

We verify pricing and regulatory data at least monthly and show a “Last verified” timestamp on every page. The category moves fast; a pricing page that was accurate last week may have changed today. If you spot a discrepancy, tell us: editorial@theglpreport.com.

Third-party links

The site includes links to provider websites and primary sources. We are not responsible for the content of third-party sites. When you sign up with a provider through an outbound link, your relationship is with that provider, subject to their terms and their clinical practice. Some outbound links are affiliate links — see our full disclosure.